Breaking News
11 hours ago
Simantini Singh Deo

FDA's final DHT guidance sets binding expectations for remote data acquisition in clinical trials, affecting protocol design and submission strategy.
Simantini Singh Deo

FDA updates its IND safety reporting resource, clarifying 21 CFR 312.32 thresholds, timelines, and submission requirements for active IND sponsors.
Simantini Singh Deo

FDA's Guidance Snapshot Pilot debuts with Master Protocols and Bayesian Methodology drafts, offering regulatory teams structured access to cross-cutting clinical trial guidance.
Simantini Singh Deo

FDA grants Roche Priority Review for a colon cancer drug, setting a 9 October 2026 decision date after trial data showed 50% recurrence reduction.
Vaibhavi M.
